The Compound — Regulation
BPC-157, TB-500, and the 2026 FDA reclassification
In April 2026 the FDA moved several popular peptides out of Category 2 restrictions, making it easier for licensed compounders to prescribe them. Here is what changed, what did not, and what the evidence actually supports.
What the reclassification actually did
The FDA maintains a list called the 503A Bulk Substances List — a catalog of substances that licensed compounding pharmacies can use in prescriptions. Category 2 on that list flagged compounds with unresolved safety or efficacy concerns. Being in Category 2 meant tighter restrictions on compounding use.
On April 15, 2026, the FDA announced it would remove BPC-157, TB-500, GHK-Cu (injectable only), and several other peptides from Category 2. Removal means licensed 503A pharmacies face fewer regulatory barriers to including these substances in patient prescriptions.
It does not mean these compounds are FDA-approved. It does not mean they are proven safe or effective in humans. It means one set of regulatory guardrails was reduced.
The three compounds and what the evidence shows
What did not change
Gray-market peptides sold as research chemicals online are still unregulated, unlicensed, and carry real contamination risk. The reclassification helps you only if you go through a licensed 503A pharmacy with a valid prescription from a physician. That path has always been the safer route. It is now more accessible.
The evidence gaps do not close because of a regulatory change. BPC-157 has not been through large-scale human trials. That is still true on April 16 as it was on April 14.
The political context
This reclassification did not happen in a vacuum. The current administration, under RFK Jr. at HHS and with DOGE reducing agency scope broadly, has been openly skeptical of what it views as FDA overreach in the supplement and peptide space. The April 2026 move was consistent with that posture.
You can read that two ways. Either the FDA had been too restrictive on compounds with plausible mechanisms and real clinical interest, and this corrects the balance. Or the safety review process is being short-circuited before the human evidence is in. Both readings have some validity. The science has not changed — only the regulatory framework around it.
How to access BPC-157 or TB-500 now
The reclassification means a physician can prescribe BPC-157 or TB-500 and a licensed 503A pharmacy can compound it. Look for a pharmacy that issues Certificates of Analysis (COAs) confirming potency and purity, and follows USP 797 standards for sterile preparations. A legitimate compounder will provide these without being asked.
Do not buy peptides from research chemical sites. The reclassification changes nothing about the quality control problems there.
The next regulatory step is a formal hearing. The FDA Pharmacy Compounding Advisory Committee has scheduled a two-day review on July 23-24, 2026 to decide whether BPC-157, TB-500, and five other peptides should be added to the 503A Bulk Drug Substances List. That outcome would give compounding pharmacies a formal, affirmative authorization rather than just reduced restrictions.
